arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

NEXGEL, INC.

NXGL
$0.40 ▲ +0.04 (+12.85%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
9 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

NEXGEL, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). On the positive side, Debt to Equity remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $3.1M
Dividend Yield
Revenue Growth 31.5%
Op. Margin -29.3%
ROIC -52.5%
FCF / Share $-0.18
Trailing P/E
Price / Book 0.7x
FCF Yield
Debt / Equity 0.13
info Valuation on last close. End-of-day price, Aug 7, 2026.

9-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$11.42M
↑ +31.5%
Net Income Profit after all expenses
$-3.00M
↑ +8.6%
Operating Margin Operating profit as % of sales
-29.3%
↑ +28.3% 8th
FCF / Share Free cash flow per share
$-0.18
↑ +73.5%
Long-Term Debt Long-term obligations
$588.00K
↓ -14.2%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
9
Returns
13
Financial Health
79
Cash Quality
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 34 quarters